The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor. However, the effects of KW-6356 combined with L-DOPA on a...

Full description

Bibliographic Details
Main Authors: Yutaro Ohno, Eri Okita, Mika Kawai-Uchida, Youji Shoukei, Kazuhiro Soshiroda, Tomoyuki Kanda, Shinichi Uchida
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:Journal of Pharmacological Sciences
Subjects:
Anti-parkinsonian
Adenosine A2A receptor Antagonist/inverse agonist
L-DOPA
Dyskinesia
MPTP
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861323000312

Internet

http://www.sciencedirect.com/science/article/pii/S1347861323000312

Similar Items